XNAS · Healthcare · Biotechnology
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | Q1 2026 | -0.62 | -0.87 | -40.32% | $887,000 | ❌ Miss | -0.21% | +3.60% | -0.64% |
| 2026-03-17 | Q4 2025 | -0.97 | -0.29 | +70.10% | $48.0M | ✅ Beat | -0.79% | -11.24% | +1.38% |
| 2025-10-30 |
| Q3 2025 |
| -1.08 |
| -0.85 |
| +21.30% |
| $11.7M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-08 | Q2 2025 | -0.94 | -1.14 | -21.28% | $2.9M | ❌ Miss | -2.68% | -2.75% | -8.50% |
| 2025-02-25 | Q4 2024 | -0.88 | -0.75 | +14.77% | $3.7M | ✅ Beat | +1.98% | -8.65% | -17.21% |
| 2024-10-31 | Q3 2024 | -0.78 | -0.74 | +5.13% | $2.7M | ✅ Beat | -3.13% | +5.35% | -14.65% |
| 2024-08-06 | Q2 2024 | -1.14 | -0.77 | +32.46% | $9.4M | ✅ Beat | -7.51% | -8.16% | -16.20% |
| 2024-05-02 | Q1 2024 | -1.24 | -0.62 | +50.00% | $19.5M | ✅ Beat | -0.45% | -4.50% | -6.72% |
Showing last 8 quarters.